Cardiovascular Disease, Dyslipidemias, Glucose Metabolism Disorders, HIV Infections, Lipodystrophy, Metabolic Diseases
Conditions
Keywords
HIV negative healthy subjects, Lipid metabolism, Glucose metabolism, Metabolic abnormality, Lipodystrophy, Cardiovascular disease, Treatment Naive, HIV
Brief summary
This is a randomised study of the effect of treatment with Combivir (zidovudine \[AZT\] and lamivudine \[3TC\]) and Kaletra (lopinavir \[LPVr\]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects.
Detailed description
Antiretroviral medications, used to treat HIV infection, cause side effects. These include changes in the way that fat is laid down on the body. This results in fat loss from some parts of the body, with fat deposits at other sites, giving a characteristic look known as HIV associated lipodystrophy or HIVLD. With these changes, there are also abnormalities in glucose and fat metabolism (collectively termed metabolic abnormalities). In HIV negative populations, these metabolic changes are associated with an increased risk of developing cardiovascular disease (CVD). The aim of this study is to investigate if changes in the body's handling of fats and glucose occur with a short course of treatment in HIV negative subjects and if these correlate to an increased risk of CVD.
Interventions
DRUGCombivir (zidovudine [AZT] / lamivudine [3TC])
DRUGKaletra (lopinavir [LPVr])
Sponsors
St Vincent's Hospital, Sydney
National Heart, Lung, and Blood Institute (NHLBI)
Garvan Institute of Medical Research
Prince of Wales Hospital, Sydney
Kirby Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age \>18 * Be able to provide written consent to perform in the trial. * HIV antibody negative and HIV DNA negative at time of entry to the study.
Exclusion criteria
* Any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial. * History of type I or type II diabetes mellitus or previous treatment with antidiabetic medication. * Prior use of testosterone, oestrogen, growth hormone or other oral glucocorticoid or anabolic steroid products within the previous six months. * Alcohol or substance abuse which in the opinion of the investigator would affect the subject's ability to participate in the trial. * Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors either in a previous study, as treatment or as part of post-exposure prophylaxis). * Prior use of any retinoid-containing compound within the previous six months. * Abnormal coagulation. * Previous allergic reaction or known allergy to local anaesthetic. * Previous use of psychotropic medications. * Concomitant use of medications, including those metabolised by CYP3A4 enzyme system, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial. * Any grade-three laboratory abnormality recorded from screening bloods. * Any grade-two laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements. * Gastrointestinal disorders, which may affect drug absorption. * Any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial. * Pregnancy * Evidence of acute or chronic active hepatitis B virus infection by serology performed at baseline. * Evidence of hepatitis C infection by serology performed at baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine effect of 6 wks ART with LPVr and CBV, alone and in combination, in HIV negative healthy subjects with respect to changes from baseline in genes related to mitochondrial and lipid metabolism in adipocytes | — |
Secondary
| Measure | Time frame |
|---|---|
| includes: To determine the effect of 6 wks of ART with LPVr and CBV in HIV negative subjects with respect to: changes from baseline in genes related to mitochondrial and lipid and glucose metabolism in monocytes. | — |
Countries
Australia
Outcome results
None listed